Form 4 for BMEA Biomea Fusion, Inc.
Accepted 2023-04-06 00:00:00 ET · period of report 2023-03-31 · accession 0001859061-23-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-06 | 2023-03-31 | BMEA | A2A Pharmaceuticals, Inc. | 10% | S - Sale | $31.25 | +200.0K | 4.10M | +5% | +$6.25M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | S | A | 200,000 | $31.25 | 4,100,000 | D | — | — | (F1) A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64 |